Search Results

• • 45 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis.

  Authors:Thierry Facon, Jesús San-Miguel, Meletios A. Dimopoulos, Maria-Victoria Mateos, Michele Cavo, Sophie van Beekhuizen, et al.From:Advances in Therapy (Vol. 39, Issue 5) Peer-Reviewed

  May 2022331 words Report, Brief articl...

   Abstract Only

• Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

  Authors:Michel Attal, Paul G Richardson, S Vincent Rajkumar, Jesus San-Miguel, Meral Beksac, Ivan Spicka, et al.From:The Lancet (Vol. 394, Issue 10214) Peer-Reviewed

  Dec. 7, 20191,124 words Report

   Abstract Only

• Risk of disease progression in asymptomatic multiple myeloma

  Authors:Meletios A. Dimopoulos, Angela Moulopoulos, Terry Smith, Kay B. Delasalle, and Raymond AlexanianFrom:American Journal of Medicine (Vol. 94, Issue 1) Peer-Reviewed

  Jan. 1993 Article

   Citation Only

• Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.

  Authors:Efstathios Kastritis, Giovanni Palladini, Monique C. Minnema, Ashutosh D. Wechalekar, Arnaud Jaccard, Hans C. Lee, et al.From:The New England Journal of Medicine (Vol. 385, Issue 1) Peer-Reviewed

  July 1, 202150 words Report

   Citation Only

• G-CSF induces elevation of circulating CA 15-3 in breast carcinoma patients treated in an adjuvant setting

  Authors:Evangelos Briasoulis, Eleni Andreopoulou, Chris F. Tolis, Eleni Bairaktari, Afroditi Katsaraki, Meletios A. Dimopoulos, et al.From:Cancer (Vol. 91, Issue 5) Peer-Reviewed

  Mar. 1, 2001 Article

   Citation Only

• Continuous Lenalidomide treatment for newly diagnosed multiple myeloma

  Authors:Antonio Palumbo, Roman Hajek, Michel Delforge, Martin Kropff, Maria Teresa Petrucci, John Catalano, et al.From:The New England Journal of Medicine (Vol. 366, Issue 19) Peer-Reviewed

  May 10, 201241 words Clinical report

   Citation Only

• Neoadjuvant chemotherapy in invasive bladder cancer

  Authors:Aristotle Bamias and Meletios A DimopoulosFrom:Expert Review of Anticancer Therapy (Vol. 5, Issue 6) Peer-Reviewed

  Dec. 20055,683 words Clinical report 1420LAuthor(s): Aristotle Bamias 1 [[dagger]] , Meletios A Dimopoulos 2 Keywords : adriamycin; bladder cancer; cisplatin; methotrexate; MVAC; neoadjuvant chemotherapy; vinblastine Bladder cancer is a common human...

• Novel approaches for concurrent irradiation in locally advanced cervical cancer: platinum combinations, non-platinum-containing regimens, and molecular targeted agents

  Authors:Giannis Mountzios, Aspasia Soultati, Dimitrios Pectasides, Meletios A. Dimopoulos, and Christos A. PapadimitriouFrom:Obstetrics and Gynecology InternationalPeer-Reviewed

  Annual 20135,796 words Article 1690LDespite the available prevention and early detection strategies, squamous-cell carcinoma of the uterine cervix is still diagnosed as locally advanced disease in a considerable proportion of patients. As a potent...

• Paclitaxel, cisplatin, and epirubicin first-line chemotherapy in stage III and IV ovarian carcinoma: long term results of a phase II study

  Authors:Christos A. Papadimitriou, Lia A. Moulopoulos, Georgios Vlahos, Zannis Voulgaris, Evangelos Kiosses, Mikolaos Georgoulias, et al.From:Cancer (Vol. 89, Issue 7) Peer-Reviewed

  Oct. 1, 2000 Article

   Citation Only

• A 50-Year-Long Study of Waldenstrom Macroglobulinemia

  Authors:Efstathios Kastritis and Meletios A. DimopoulosFrom:Mayo Clinic Proceedings (Vol. 94, Issue 3) Peer-Reviewed

  Mar. 20191,664 words Report 1630LWaldenstrom macroglobulinemia (WM) is a rare low-grade lymphoma in which lymphoplasmacytic cells infiltrate the bone marrow and produce monoclonal IgM protein. (1) It has a well-defined immunophenotype, although...

• Paraneoplastic Cushing's syndrome as an adverse prognostic factor in patients who die early with small cell lung cancer

  Authors:Meletios A. Dimopoulos, Jose F. Fernandez, Naguib A. Samaan, Paul Y. Holoye, and Rena Vassilopoulou-SellinFrom:Cancer (Vol. 69, Issue 1) Peer-Reviewed

  Jan. 1, 1992318 words Article

   Abstract Only

• Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.

  Authors:Sebastian Grosicki, Maryana Simonova, Ivan Spicka, Ludek Pour, Iryrna Kriachok, Maria Gavriatopoulou, et al.From:The Lancet (Vol. 396, Issue 10262) Peer-Reviewed

  Nov. 14, 20201,296 words Article

   Abstract Only

• Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis.

  Authors:Vania Hungria, Deborah M. Martínez-Banos, María-Victoria Mateos, Meletios A. Dimopoulos, Michele Cavo, Bart Heeg, et al.From:Advances in Therapy (Vol. 37, Issue 12) Peer-Reviewed

  Dec. 2020421 words Report

   Abstract Only

• Diagnostic work-up and specific causes of acute kidney injury

  Authors:Michael Darmon, Marlies Ostermann, Jorge Cerda, Meletios A. Dimopoulos, Lui Forni, Eric Hoste, et al.From:Intensive Care Medicine (Vol. 43, Issue 6) Peer-Reviewed

  June 2017524 words Author abstract, Rep...

   Abstract Only

• Aberrant DNA Damage Response Pathways May Predict the Outcome of Platinum Chemotherapy in Ovarian Cancer

  Authors:Dimitra T. Stefanou, Aristotelis Bamias, Hara Episkopou, Soterios A. Kyrtopoulos, Maria Likka, Theodore Kalampokas, et al.From:PLoS ONE (Vol. 10, Issue 2) Peer-Reviewed

  Feb. 6, 20158,462 words Article 1510LOvarian carcinoma (OC) is the most lethal gynecological malignancy. Despite the advances in the treatment of OC with combinatorial regimens, including surgery and platinum-based chemotherapy, patients generally exhibit...

• Anti-tumor immune response in ovarian cancer: clinical implications, prognostic significance and potential for novel treatment strategies

  Authors:Nikos G. Gavalas, Meletios A. Dimopoulos, and Aristotelis BamiasFrom:Oncology Reviews (Vol. 3, Issue 3)

  Sept. 2009279 words Clinical report

   Abstract Only

• Pharmacokinetics and Exposure--Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma

  Authors:Xu Steven Xu, Meletios A. Dimopoulos, Pieter Sonneveld, P. Joy Ho, Andrew Belch, Merav Leiba, et al.From:Advances in Therapy (Vol. 35, Issue 11) Peer-Reviewed

  Nov. 2018535 words Report

   Abstract Only

• Prevalence of BRCA1 Mutations in Familial and Sporadic Greek Ovarian Cancer Cases

  Authors:Alexandra V. Stavropoulou, Florentia Fostira, Maroulio Pertesi, Marianthi Tsitlaidou, Gerassimos E. Voutsinas, Olga Triantafyllidou, et al.From:PLoS ONE (Vol. 8, Issue 3) Peer-Reviewed

  Mar. 11, 20135,654 words Clinical report 1550LGermline mutations in the BRCA1 and BRCA2 genes contribute to approximately 18% of hereditary ovarian cancers conferring an estimated lifetime risk from 15% to 50%. A variable incidence of mutations has been reported...

• Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

  Authors:Maria-Victoria Mateos, Michele Cavo, Joan Blade, Meletios A Dimopoulos, Kenshi Suzuki, Andrzej Jakubowiak, et al.From:The Lancet (Vol. 395, Issue 10218) Peer-Reviewed

  Jan. 11, 20201,005 words Article

   Abstract Only

• Ifosfamide, paclitaxel and cisplatin first-line chemotherapy in advanced, suboptimally debulked epithelial ovarian cancer

  Authors:Christos A. Papadimitriou, Charalambos Kouroussis, Lia A. Moulopoulos, Georgios Vlahos, Alexandros Rodolakis, Christos Kiamouris, et al.From:Cancer (Vol. 92, Issue 7) Peer-Reviewed

  Oct. 1, 2001 Article

   Citation Only